- John Isaacs (Chair)
- Edward Vital: The Bruton’s Tyrosine Kinase pathway – an attractive target in autoimmune disease?
- David Isenberg: Targeting the BTK pathway in SLE
- Stanley Cohen: Targeting the BTK pathway in RA